Pharma Industry News

AZ’ Tagrisso improves overall survival in lung cancer

The trial previously met its primary endpoint in July 2017, showing a statistically-significant and clinically-meaningful improvement in progression-free survival.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]